Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Core Insights - Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes without the systemic side effects associated with current therapies [3]. Group 1 - The company will have its president and CEO, René Russo, participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 9:50 am EST [1]. - A live webcast of the event will be available on the Xilio Therapeutics website, with a replay accessible for 30 days post-presentation [2]. Group 2 - Xilio Therapeutics utilizes a proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical immuno-oncology molecules, which are designed to optimize therapeutic efficacy by targeting the tumor microenvironment [3].